MedTrace Logo

Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19

NCT05045937 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2022-04-27

No results posted yet for this study

Summary

Ivermectin is currently being utilized by a number of physicians in the local area. My objective will be to enroll these patients at the time of their evaluation for COVID-19 infection and to follow their progress through their recovery.

Conditions

Interventions

DRUG

Ivermectin

Ivermectin treatment of outpatients dosing at 0.4mg/kg until recovered along with supplemental treatment using a multi-modal approach.

Sponsors & Collaborators

  • Patrick Robinson

    lead OTHER

Principal Investigators

  • Patrick r Robinson, MD · Patrick Robinson MD LLC

Eligibility

Min Age
12 Years
Max Age
110 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2024-05-01
Completion
2024-05-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05045937 on ClinicalTrials.gov